Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Rosiglitazone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 15/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.87 |
| ▸ | RARG | P13631 | 1/20 | 0.87 |
| ▸ | PPARA | Q07869 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Rosiglitazone SCHEMBL29530259 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL7052472 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL11957687 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL2355017 | 1.00 | PPARG (1.00) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3375739 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL6976956 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL1489117 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3377103 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL5468691 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 | |
| Rosiglitazone SCHEMBL3381790 | 0.99 | PPARG (0.98) | PPARGRXRARARGPPARAFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 65068 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| US-12624116-B2 | Methods of treating severe insulin resistance by interfering with glucagon receptor signaling | REGENERON PHARMACEUTICALS, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20260124282-A1 | DECORIN FOR ITS USE IN THE TREATMENT OF DIABETES | CENTRE EUROPEEN D'ETUDE DU DIABETE (FR) | 2026-05-07 | — | — | US | claimed |
| US-20260115145-A1 | Method for Enhancing Drug Solubility and Preparing a Drug Composite Material with Enhanced Solubility | PHARMAEASE TECH LTD (CN) | 2026-04-30 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4731202-A1 | METHODS FOR MEASURING METABOLIC DYSFUNCTION OR RISK OR PRESENCE OF AN AGE-ASSOCIATED DISEASE | Loyal Animal Health, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| US-12605354-B2 | Azelaic acid esters in the treatment or prevention of dyslipidemia and associated conditions | NEW FRONTIER LABS, LLC (US) | 2026-04-21 | — | — | US | claimed |
| US-12599564-B2 | Antidiabetic pharmaceutical compositions | Elite Pharmaceutical Solution Inc. (US) | 2026-04-14 | — | — | US | claimed |
| US-20260097039-A1 | METHODS FOR TREATING A FATTY LIVER DISEASE | MADRIGAL PHARMACEUTICALS INC (US) | 2026-04-09 | — | — | US | claimed |
| EP-0719140-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | Sankyo Company Limited (JP) | 1996-07-03 | — | — | EP | claimed |
| EP-0695183-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1996-02-07 | — | — | EP | claimed |
| WO-1995021608-A1 | USE OF INSULIN SENSITISERS FOR TREATING RENAL DISEASES | SMITHKLINE BEECHAM PLC (GB) | 1995-08-17 | — | — | WO | claimed |
| EP-0658161-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1995-06-21 | — | — | EP | claimed |
| WO-1995007694-A1 | USE OF THIAZOLIDINEDIONES TO PREVENT OR DELAY ONSET OF NIDDM | SANKYO COMPANY, LIMITED (JP) | 1995-03-23 | — | — | WO | claimed |
| WO-1994025026-A1 | USE OF THIAZOLIDINEDIONES FOR THE TREATMENT OF ATHEROSCLEROSIS AND EATING DISORDERS | SMITHKLINE BEECHAM PLC (GB) | 1994-11-10 | — | — | WO | claimed |
| WO-1994005659-A1 | SUBSTITUTED THIAZOLIDINEDIONE DERIVATIVES | SMITHKLINE BEECHAM PLC (GB) | 1994-03-17 | — | — | WO | claimed |
| US-5232925-A | Treating hypertension | BEECHAM GROUP P.L.C. (GB) | 1993-08-03 | — | — | US | claimed |
| US-5002953-A | Substituted Thiazolidinedione Derivatives | BEECHAM GROUP P.L.C. (GB) | 1991-03-26 | — | — | US | claimed |
| EP-0306228-A1 | Substituted thiazolidinedione derivatives | BEECHAM GROUP PLC (GB) | 1989-03-08 | — | — | EP | claimed |